Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019

por Razonable, Raymund R, Ganesh, Ravindra, Bishop, Rachel K, Culbertson, Tracy L, Destro Borgen, Molly, Hedin, Michelle C, Hopkins, Laura H, Jackson, Tammy A, Larsen, Jennifer J, Matoush, Jennifer A, Moehnke, Darcie E, Olson, Shelly M, Peterson, Kellie M, Rosedahl, Jordan, Philpot, Lindsey M
Publicado 2022

Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19

por Razonable, Raymund R., Pawlowski, Colin, O'Horo, John C., Arndt, Lori L., Arndt, Richard, Bierle, Dennis M., Borgen, Molly Destro, Hanson, Sara N., Hedin, Michelle C., Lenehan, Patrick, Puranik, Arjun, Seville, Maria T, Speicher, Leigh L., Tulledge-Scheitel, Sidna M., Venkatakrishnan, AJ, Wilker, Caroline G., Badley, Andrew D., Ganesh, Ravindra
Publicado 2021